Abstract. Peptide nucleic acids (PNAs) are DNA mimics constituted by a pseudopeptide backbone composed of N-(2-aminoethyl)glycine units. PNAs hybridize with high affinity to complementary sequences of single-stranded RNA and DNA, forming Watson-Crick double helices and are resistant to both nucleases and proteases. While applications of PNAs as antisense and antigene molecules have been described, PNA/ DNA and PNA/PNA hybrids are not useful for transcription factor decoy (TFD) pharmacotherapy. By contrast, PNA-DNA-PNA (PDP) chimeras, constituted of sequential PNA, DNA and PNA stretches, are potent decoy molecules in vitro. Interestingly, PDP-based decoys a) are more soluble than PNAs, b) are more resistant than synthetic oligonucleotides to enzymatic activity present in cellular extracts and serum and c) can be delivered with liposomes. In the present study we demonstrated that double-stranded PNA-DNA-PNA chimeras targeting NF-κB transcription factors induce apoptosis of human primary osteoclasts. Our data suggest that PDP-based induction of osteoclast apoptosis could be a therapeutic approach for disorders in which bone resorption is inappropriately excessive.
Introduction
The nuclear transcription factors belonging to the NF-kappaB (NF-κB) superfamily are involved in several normal biological processes, as well as in human pathologies (1) (2) (3) (4) . For instance, the involvement of NF-κB in inflammation is well known, as well as the requirement of NF-κB activity in viral infection (5, 6) . Therefore, molecular biology approaches aimed at the control of NF-κB activity have been in the past objects of several investigations (7) (8) (9) (10) (11) .
Among non-viral gene therapy strategies able to inhibit or even block NF-κB activity, the transcription factor decoy (TFD) approach (12) (13) (14) should be taken into consideration, since NF-κB decoys have been recently used in several preclinical studies and proven to be active in several experimental systems (15) (16) (17) (18) (19) (20) . For instance, Ogushi et al (21) recently assessed the efficacy of in vivo transfer of synthetic TFD oligodeoxyribonucleotides (ODN) against NF-κB as a therapeutic strategy for treating endotoxin-induced fetal liver injury. NF-κB decoys were preferentially transferred to Kupffer cells, and activation of NF-κB was suppressed, leading to decreased inflammatory cytokine production. As a result, the massive necrosis observed in the control mice was dramatically attenuated and the survival rate improved (19) . In addition, decoy ODNs were demonstrated to be useful to inhibit tumor cell growth and invasion (20, 22) , as anti-inflammatory agents (23, 24) , in myocardial preservation (25) (26) (27) (28) , in cerebral angiopathy (29) .
These decoy activities against NF-κB were achieved by using as decoy molecules synthetic oligonucleotides carrying NF-κB specific cis-elements. Unfortunately, synthetic ODNs are not stable in vivo or ex vivo and, therefore, should be extensively modified in order to be used (15, (30) (31) (32) (33) (34) (35) .
In recent reports, we have proposed peptide nucleic acids (PNAs) as alternative reagents in experiments aimed at the INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 14: 145-152, 2004 1 4 5 Peptide nucleic acid-DNA decoy chimeras targeting NF-κB transcription factors: Induction of apoptosis in human primary osteoclasts control of gene expression involving the TFD approach (7, (36) (37) (38) . In PNAs, the pseudopeptide backbone is composed of N-(2-aminoethyl)glycine units (39, 40) . PNAs hybridize with high affinity to complementary sequences of single-stranded RNA and DNA, forming Watson-Crick double helices (41) and are resistant to both nucleases and proteases (42) . Even without considering studies on effects on cultured cells, Romanelli et al (7) demonstrated, for the first time, that PNA-DNA-PNA (PDP) chimeras mimicking the NF-κB binding sites are capable of stable interaction with both purified NF-κB p52 and p50, as well as nuclear factors from B-lymphoid cells. This highly interesting feature of PDP chimeras was confirmed studying molecules carrying the binding sites for other transcription factors, such as Sp1 (38) .
In agreement with these reports, we concluded that PNA-DNA-PNA chimeras deserve to be analysed for biological activity, in order to propose these molecules for the development of potential agents for a decoy approach in gene therapy.
In this respect, osteoclasts (OCs) are a very useful experimental system (43) . In fact, proteins belonging to the NF-κB superfamily are involved in osteoclast formation, playing a very important role for both differentiation of osteoclast precursors and survival of mature osteoclasts. In this respect, targeting of NF-κB transcription factor could be of great interest (44) (45) (46) (47) (48) . In a recent study, we examined the effects of decoy DNA/DNA molecules targeting NF-κB on apoptosis of human osteoclasts, with the aim to interfere with the pathway regulating osteoclast differentiation and programmed cell death (49) .
The aim of the present study was to verify whether PNA-DNA-PNA chimeras mimicking the binding site recognized by NF-κB are able to induce apoptosis of primary human osteoclasts. To this aim, a mixture of receptor activator of NF-κB ligand (RANKL), macrophage colony-stimulating factor (M-CSF) and parathyroid hormone (PTH) to prepare human OCs from peripheral blood cells was used. Then, transfection of osteoclasts with the decoy molecules based on PNA-DNA-PNA chimeras and targeting NF-κB was performed.
Materials and methods
Synthetic oligonucleotides and production of NF-κB PNA-DNA-PNA chimeras. The synthetic oligonucleotides used in this study were purchased from Sigma (St. Louis, MO, USA). PNA monomers for production of PNA-DNA chimeras were synthesized in the laboratories of Professor J.H. van Boom (50) (Leiden Institute of Chemistry, Gorlaeus Laboratories, Leiden University, The Netherlands); DNA monomers were obtained from Perseptive Biosystems. Methanol (Rathburn, HPLC grade) was stored over molecular sieves (3 Å) and used without other purification. All the other solvents (Biosolve DNA synthesis grade) were used as received. Automatized synthesis of the chimeras was performed on a Pharmacia Gene Assembler, using highly cross-linked polystyrene (loading 26-28 µmol/g) as the solid support on a 1-µmol scale, as reported elsewhere (7) . After the last elongation step, the oligomers were cleaved from the solid support and deprotected by treatment with 1.5 ml methanolic ammonia, at 50˚C for 16 h. The samples were filtered and then purified by RP-HPLC on a LiChrosphere 100 RP-18 endcapped column (4x250 mm) on a Jasco HPLC system. Gradient elution was performed at 40˚ building up gradient starting with buffer A (50 mM triethylammonium acetate in water) and applying buffer B (50 mM triethylammonium acetate in acetonitrile/water, 1/1, v/v), with a flow rate of 1 ml/min. Chimera 1: HPLC purity 100%, t R = 18 min (gradient 3-20% B in 25 min); chimera 2: HPLC purity 100%, t R = 16 min (gradient 5-25% B in 25 min). HPLC-MS analysis was carried out on a Jasco LCMS system equipped with a LiChrosphere 100 RP-18 endcapped column (4x250 mm) using a gradient of acetonitrile in 10 mM ammonium acetate buffer with mass detection on a PerkinElmer Sciex API 165 equipped with an Electrospray Interface (ESI). 
Electrophoretic mobility shift assay. The electrophoretic mobility shift assay (EMSA) (38,51) was performed by using the double-stranded synthetic oligonucleotides mimicking NF-κB binding sites (the nucleotide sequences are reported in Fig. 1 ). The target molecules were 5'-end-labelled using [ Á-32 P]ATP and T4 polynucleotide kinase (MBI Fermentas, Italy) in the case of DNA/DNA and DNA/PDP (36) . [ 32 P]-labelled PDP/PDP molecules were produced by nick-translation, using low concentration of DNase and [Á-
32 P]dCTP (36) . Binding reactions were set up as described elsewhere (7) in a total volume of 25 µl containing buffer TF + 5% glycerol, 1 mM DTT, 10 ng of human NF-κB p52 protein (Promega Corp., Madison, WI) or 1 µg of crude nuclear extracts from B-lymphoid Raji and human leukemic K562 cells (7, 38) and 0.25 ng of [ 32 P]-labelled oligonucleotides. After 30 min binding at room temperature, the samples were electrophoresed at constant voltage (200 V) under low ionic strength conditions (0.25X TBE buffer = 22 mM Tris-borate, 0.4 mM EDTA) on 6% polyacrylamide gels. Gels were dried and subjected to standard autoradiographic procedures (36) . In competition experiments, the competitor molecules carrying NF-κB binding sites (DNA/DNA, DNA/PDP, PDP/DNA and PDP/PDP) were preincubated for 20 min with purified NF-κB p52 protein before the addition of labelled target DNA. The nucleotide sequences of competitor double-stranded target DNAs used as controls were: 5'-TAA TAT GTA AAA ACA TT-3' (sense strand, NF-IL2A) and 5'-CAC TTG ATA ACA GAA AGT GAT AAC TCT-3' (sense strand, GATA-1).
Liposome preparation. Egg phosphatidyl choline was purchased from Lipid Products (Surrey, England). Tetralysinecholesterol (Lys 4 -Chol) was a generous gift of Professor Marastoni (Department of Pharmaceutical Sciences, University of Ferrara). Positively charged liposomes were produced by a protocol based on reverse phase evaporation followed by extrusion of the liposome suspension through polycarbonate filters with homogeneous pore size (36,52). Liposomes were PENOLAZZI et al: APOPTOSIS IN HUMAN PRIMARY OSTEOCLASTS subjected to one extrusion cycle through two stacked 400 nm pore size filters followed by three extrusion cycles through two stacked 200 nm pore size membranes, in order to obtain unilamellar liposomes with a homogeneous size distribution. The complexation of PNA-DNA chimeras to liposomes was performed just before the analysis, simply mixing the target decoy molecules to 'preformed' cationic vesicles, employing increasing liposome concentrations, including those which were known to cause a full complexation of target DNA/DNA hybrids (36) (37) (38) . The verification of the obtained complexation of NF-κB DNA/DNA, DNA/PDP and PDP/PDP hybrids to liposomal formulations was reached following electrophoresis through an agarose gel and autoradiographic procedure (in the case of DNA/DNA or DNA/PDP) or staining with ethidium bromide (in the case of PDP/PDP molecules).
Resistance of decoy molecules. The resistance of [ 32 P]-labelled DNA/DNA and DNA/PDP target molecules was evaluated as follows: the decoy molecules were incubated without or with different concentrations (2-25 µg/reaction) of Lys 4 -Chol for 30 min at room temperature and then serum (fetal calf serum, Eurobio, France; 30 g/l protein concentration) was added (3 µl/reaction). After overnight incubation, the reactions were phenol-extracted, ethanol-precipitated, electrophoresed through a polyacrylamide gel and autoradiography was performed. Disappearance of the decoy molecule was considered as an evidence of degradation (37) .
Culture of human primary OCs. Human OCs were prepared as reported by Matsuzaki et al (53) with slight modifications. Briefly, peripheral blood was collected from healthy normal volunteers after informed consent. Mononuclear cells (PBMCs) were prepared from diluted peripheral blood (1:2 in Hanks' balanced salt solution), which was layered over Histopaque 1077 (Sigma) solution, centrifuged (400 g), washed and resuspended in D-MEM/10% FCS. 3x10 6 PBMCs/cm 2 were plated in 24-well plates or in chamber slides and allowed to settled for 2 h; wells were then rinsed to remove non-adherent cells. Monocytes were maintained at 37˚C, in 5% CO 2 , in medium supplemented with 10% FCS and cultured for 14 days in the presence of human M-CSF (25 ng/ml), RANKL (30 ng/ ml) and 10 -7 M PHT. Culture media were replenished with fresh media every 3-4 days. Cells were used for the described experiments when mature multinuclear cells were predominant in the cultures. (54) . Cells were fixed in 3% paraformaldehyde with 0.1 M cacodilic buffer, pH 7.2 (0.1 M sodium cacodilate, 0.0025% CaCl 2 ) for 15 min, exstensively washed in the same buffer, and stained for TRAP (Acid Phosphatase Kit no. 386-Sigma). After washing with distilled water and drying, mature TRAP positive multinucleated cells containing more than three nuclei were counted as osteoclasts. Immunocytochemistry analysis was performed employing the streptavidin-biotin method using Ultraystain Polyvalent-HRP Immunostaining Kit (Ylem, Rome, Italy). OCs cells grown in multichamber slides were fixed in 100% cold methanol, and permeabilized with (v/v) Triton X-100 (Sigma) in TBS (Tris-buffered saline). Cells were incubated in 3% H 2 O 2 and blocked with Super Block reagent (Ultraystain Polyvalent-HRP Immunostaining Kit). After the reaction with the primary antibodies, the rabbit polyclonal antibody of human origin (Santa Cruz Biotech, Santa Cruz, CA, USA) against MMP9 was used according to the manufacturer's protocols, at 1:500 dilution; incubation was carried out at 4˚C for 16 h. Cells were then incubated at room temperature with anti-polyvalent biotinylated antibody (Ultraystain Polyvalent-HRP Immunostaining Kit). After rinsing in TBS, Streptavidin HRP (Ultraystain Polyvalent-HRP Immunostaining Kit) was applied, followed by the addition of substrate-chromogen mix (AEC Cromogeno Kit, Ylem). After washing, cells were mounted in glycerol/TBS 9:1 and observed using a Leitz microscope. Statistical analysis. Data are presented as the mean ± SEM from at least three independent experiments. Statistical analysis was performed by one-way analysis of variance followed by the Student's t-test. A p-value <0.001 was considered statistically significant. (Fig. 2A) . This binding is specific, since is competed by addition of cold NF-κB DNA/DNA and DNA/PDP (Fig. 2A,  lanes a and b, and data not shown) . Accordingly, the same cold double-stranded NF-κB PDP/PDP, PDP/DNA and DNA/PDP molecules are able to inhibit the interactions between crude unfractionated nuclear factors from B-lymphoid Raji cells and target [ 32 P]-labelled NF-κB DNA/DNA probe (Fig. 2B) . The results obtained strongly suggest that, under these experimental conditions, the double-stranded decoy molecules based on PNA-DNA-PNA chimeras efficiently bind to NF-κB transcription factors. Furthermore, we demonstrated that addition of cold double-stranded PDP/PDP, PDP/DNA, and DNA/PDP molecules do not affect the binding of NF-IL2A and GATA-1 factors to the respective target [ 32 P]-labelled DNA/DNA probes (Fig. 2C) . The experiment reported in Fig. 2C was performed using [ 32 P]-end labelled NF-IL2A and GATA-1 DNA-DNA target molecules and nuclear factors isolated from Raji and K562 cell lines, respectively. Similar results were obtained using [ 32 P]-end labelled STAT-1 DNA-DNA target molecules (data not shown). Therefore, these results firmly establish that the effects of PNA-DNA chimeras are sequence-specific.
Tartrate-resistant acid phosphatase (TRAP) staining and immunocytochemistry analysis. TRAP staining of the cells was performed as reported by Villanova et al

DNA transfection and decoy experiments.
Results
Synthetic oligonucleotides and PNA-DNA-PNA chimeras.
Effects of the NF-κB DNA/DNA decoy molecules on primary human osteoclasts. After 14 days of cell culture in the presence of RANKL, M-CSF and PTH, human OCs obtained from peripheral blood were analysed for the expression of the osteoclast-associated enzyme tartrate-resistant acid phosphatase (TRAP) and MMP9 (the scheme of the experiment is outlined in Fig. 3A ). Fig. 3B shows representative examples of TRAP-positive and MMP9-positive cells after 7, 14 and 21 days, demonstrating that OCs are obtained in these experimental conditions. Most of them were multinucleated and likely represent prefusion osteoclasts, since they also express the MMP9 osteoclast-associated antigen (46) , being on the contrary negative to immunostaining with monoclonal antibody GSR1, recognizing the macrophage-associated antigen CD14, not expressed by osteoclasts (47) (data not shown).
The effects of the double-stranded decoy ODN targeting NF-κB were analyzed on isolated multinucleated cells in terms of apoptosis. We treated primary OCs with the NF-κB HIV-1 decoy molecule complexed with PC:DOTAP cationic liposomes using DNA and lipid dosages previously determined in other cells types (56) (57) (58) to retain functional activity without affecting cell viability. Since data from literature indicate that a lipid formulation can display a differential toxicity on different cultured cells, a first set of experiments was addressed to investigate whether the employed liposomal formulations display cytotoxicity in osteoclasts. The adherent cells were treated with different amounts of cationic liposomes in combination with unrelated (scrambled) ODN, and viable cells were quantified by a colorimetric assay with Thiazolyl blue (MTT assay). Notably, treatment with 1 µg/µl of DNA/liposome complex failed to yield any cytotoxic effect on the total cell population and on osteoclasts, indicating that the conditions employed for the decoy approach did not decrease cell viability (data not shown). Fig. 4A ) and that this complexation protects these molecules from degradation when incubated in the presence of serum (see the representative experiment shown in Fig. 4B ). The details of liposome complexation and protection from degradation in the presence of serum and cellular extracts have been reported by Borgatti et al (38) .
Effects of the NF-κB
Mature osteoclasts and TRAP-positive precursors were therefore treated with 1 µg/µl of the decoy molecules for 48 h and then subjected to analysis of apoptosis. Morphological analysis of NF-κB decoy-treated osteoclasts demonstrated cell retraction in comparison with unrelated ODN control-treated osteoclasts (see the representative experiment shown in Fig. 5A and B), indicative of apoptosis. Several nuclei showed morphological changes consistent with nuclear damage. Therefore, after treatment with the decoy against NF-κB on day 14 (when osteoclast differentiation was complete), a great change in cell survival of osteoclasts was observed.
To confirm apoptosis, TUNEL staining of fragmented DNA was performed. As shown in Fig. 5C NF-κB decoy caused programmed cell death at a very early stage with more than 13-fold increase in the percentage of apoptotic osteoclasts. In addition, the results obtained demonstrated that all the PDP-based decoy molecules were able to induce apoptosis of primary OCs.
Discussion
The main issue of this study was to verify whether PNA-DNA-PNA (PDP) chimeras targeting NF-κB transcription factors induce apoptosis of human primary osteoclasts. The results obtained firmly demonstrated that PDP chimeras against NF-κB are powerful inducers of apoptosis of human osteoclasts. This is the first observation of biological activity of these reagents, when administered to target cells.
In PNAs, the pseudopeptide backbone is composed of N-(2-aminoethyl)glycine units (40, 59) . PNAs hybridize with high affinity to complementary sequences of single-stranded RNA and DNA, forming Watson-Crick double helices (39, 41) and are resistant to both nucleases and proteases (42) . However, PNA/DNA and PNA/PNA hybrids are not useful for applications in the transcription factor decoy (TFD) pharmacotherapy (40, 51, 60) . In this respect PDP-based decoys are of great interest since: a) PDP are more soluble than PNAs (40), b) PDP are more resistant than ODNs to enzymatic activity present in cellular extracts and serum (38) and c) PDP can be delivered with liposomes (36) .
The effects of PDP-based NF-κB decoys are related to the involvement of this transcription factor on biological functions of OCs. Accumulating evidence indicates indeed that NF-κB is associated with activation of osteoclasts and is important for both differentiation of osteoclast precursors and survival of mature osteoclasts (46) .
Even if further studies addressing a) the identification of candidate genes regulated by NF-κB important for osteoclast survival and b) the mechanisms by which NF-κB inhibition stimulates osteoclast apoptosis (including the detailed analysis of the effects of NF-κB decoys on all the pro-apoptotic and apoptosis-associated genes) are necessary, we suggest that the induction of apoptosis after NF-κB decoy treatment obtained in primary osteoclasts from peripheral blood, could be also obtained in other tissue environments and used in the control of bone formation. Accordingly, promotion of osteoclast apoptosis has become a very important therapeutic target for disorders in which bone resorption is inappropriately excessive.
The potent therapeutic agents employed at present, such as estrogen and aminobisphosphonates, have side effects that limit their systemic use.
Therefore, the development of a strategy based on nucleic acid drugs and analogues, such as described herein, may be of great interest for therapeutics optimized for both safety and efficacy.
